Bill Detail
H.R. 1117
Congress: 119
Title
Responsibility in Drug Advertising Act of 2025
Summary
Responsibility in Drug Advertising Act of 2025 This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media. Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources. The prohibition applies to new drugs approved beginning one year before the bill’s enactment.
Sponsor
Rep. Rosa DeLauro [D-CT-3]
Status
Referred to the House Committee on Energy and Commerce.
Status as of Jul 25, 10:52 PM · synced 19d ago
Introduced
2025-02-07
Data source mode: congress-gov
Bill Engagement
Responsibility in Drug Advertising Act of 2025 This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food…
Lobbyists on the case
- America's Health Insurance Plans, Inc. (AHIP)1 filing · 12 lobs
Prepared intelligence brief
Put this record in the joined picture.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.